secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2026-06-18T21:14:49+00:00
Accession:  0001104659-26-075849
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros Pharmaceuticals CFO Arnold departs; Robert Weinstein appointed as CAO/PFO
--------------------------------------------------------------------------------

- Mitchell Arnold mutually separated as VP Finance, Principal Financial & Accounting Officer, effective June 18, 2026.
- Robert Weinstein appointed as Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer, effective immediately.
- Separation includes $38,500 severance (2 months salary), accelerated vesting of 3,000 unvested shares, and 2 months COBRA premium subsidy.
- Weinstein brings 30+ years experience; most recently CFO of TAO Synergies (formerly Synaptogenix) since 2013.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465926075849/0001104659-26-075849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465926075849/tm2618334d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-075849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer